Evaluating the effect of Empagliflozin or Silymarin and vitamin E on the course of fatty liver disease

Evaluating the effect of Empagliflozin or Silymarin and vitamin E on the course of fatty liver disease in non-diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241126063860N1

Enrollment

108

Registered

2025-02-21

Start date

2025-02-28

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Control group: In this group, 36 patients will receive standard drug treatment (diet, lifestyle modification, and daily vitamin E capsules of 200 international units from Dana Pharma-I

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with diabetes aged 20 to 65 years

Exclusion criteria

Exclusion criteria: Alcohol consumption Types of hepatitis Heart failure Kidney failure

Design outcomes

Primary

Measure	Time frame
Fatty liver grade. Timepoint: 3 months and 6 months after the start of the study. Method of measurement: Liver ultrasound.;Aspartate aminotransferase. Timepoint: 3 months and 6 months after the start of the study. Method of measurement: Biosystems Laboratory Kit.;Alanine aminotransferase. Timepoint: 3 months and 6 months after the start of the study. Method of measurement: Biosystems Laboratory Kit.;Body Mass Index. Timepoint: 3 months and 6 months after the start of the study. Method of measurement: the body mass divided by the square of the body height.	—

Measure

Time frame

Fatty liver grade. Timepoint: 3 months and 6 months after the start of the study. Method of measurement: Liver ultrasound.;Aspartate aminotransferase. Timepoint: 3 months and 6 months after the start of the study. Method of measurement: Biosystems Laboratory Kit.;Alanine aminotransferase. Timepoint: 3 months and 6 months after the start of the study. Method of measurement: Biosystems Laboratory Kit.;Body Mass Index. Timepoint: 3 months and 6 months after the start of the study. Method of measurement: the body mass divided by the square of the body height.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShadi Erfanian Asl

Arak University of Medical Sciences

Sh.physician@gmail.com+98 86 3417 3914

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026